Q1 EPS Estimates for Legend Biotech Raised by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for shares of Legend Biotech in a research note issued on Thursday, July 17th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of $0.14 for the quarter, up from their previous forecast of $0.08. HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Legend Biotech’s Q3 2026 earnings at $0.44 EPS and Q4 2026 earnings at $0.76 EPS.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.33. Legend Biotech had a negative return on equity of 21.19% and a negative net margin of 29.95%. The firm had revenue of $195.05 million for the quarter, compared to the consensus estimate of $190.83 million. During the same period in the prior year, the business posted ($0.16) earnings per share. The company’s revenue for the quarter was up 107.8% on a year-over-year basis.

Several other research analysts also recently commented on LEGN. Cantor Fitzgerald restated an “overweight” rating and set a $55.00 price objective on shares of Legend Biotech in a report on Wednesday, May 14th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $84.00 price target on shares of Legend Biotech in a report on Tuesday, April 22nd. UBS Group set a $54.00 price target on Legend Biotech and gave the company a “buy” rating in a report on Wednesday, July 2nd. Truist Financial cut their price target on Legend Biotech from $88.00 to $71.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Finally, Johnson Rice reiterated a “buy” rating on shares of Legend Biotech in a report on Thursday. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Legend Biotech presently has an average rating of “Moderate Buy” and a consensus price target of $73.33.

Legend Biotech Trading Down 1.3%

Shares of NASDAQ LEGN opened at $41.59 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.07 and a current ratio of 5.20. The business’s 50 day moving average price is $33.81 and its 200-day moving average price is $34.44. Legend Biotech has a fifty-two week low of $27.34 and a fifty-two week high of $60.87. The company has a market cap of $7.64 billion, a price-to-earnings ratio of -70.49 and a beta of 0.19.

Hedge Funds Weigh In On Legend Biotech

Institutional investors have recently modified their holdings of the stock. Westfield Capital Management Co. LP increased its stake in Legend Biotech by 21.1% during the 1st quarter. Westfield Capital Management Co. LP now owns 6,917,567 shares of the company’s stock worth $234,713,000 after buying an additional 1,203,871 shares in the last quarter. Suvretta Capital Management LLC purchased a new stake in Legend Biotech during the 4th quarter worth approximately $113,767,000. Invesco Ltd. increased its stake in Legend Biotech by 44.7% during the 4th quarter. Invesco Ltd. now owns 3,309,971 shares of the company’s stock worth $107,706,000 after buying an additional 1,022,365 shares in the last quarter. Braidwell LP increased its stake in Legend Biotech by 93.2% during the 4th quarter. Braidwell LP now owns 2,977,951 shares of the company’s stock worth $96,903,000 after buying an additional 1,436,400 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Legend Biotech by 0.3% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 2,270,264 shares of the company’s stock valued at $77,030,000 after purchasing an additional 6,708 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).